Showing results (201-210 of 265) with videos related to
Sort By:
Pageof 27
Lung Cancer (Amsterdam, Netherlands)|October 14, 2019
Perioperative course and quality of life in a prospective randomized multicenter phase III trial, comparing standard lobectomy versus anatomical segmentectomy in patients with non-small cell lung cancer up to 2 cm, stage IA (7th edition of TNM staging system)Georgios Stamatis, Gunda Leschber, Birte Schwarz, et al.Scientific Reports|October 30, 2020
Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesotheliomaSabrina Borchert, Pia-Maria Suckrau, Robert F H Walter, et al.Immunotherapy|July 13, 2022
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factorsMaja Guberina, Nika Guberina, Christoph Pöttgen, et al.Journal of Hazardous Materials|July 8, 2025
Small Particles, Big Problems: Polystyrene nanoparticles induce DNA damage, oxidative stress, migration, and mitogenic pathways predominantly in non-malignant lung cellsBüsra Ernhofer, Andreas Spittler, Franziska Ferk, et al.Nature Communications|May 6, 2026
A single-cell atlas revealing cellular heterogeneity across healthy and diseased human thymusMartin Direder, Matthias Wielscher, Melanie Salek, et al.Radiation Oncology (London, England)|September 16, 2021
Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definitionMaja Guberina, Kaid Darwiche, Hubertus Hautzel, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2021
PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPYMaja Guberina, Christoph Poettgen, Martin Metzenmacher, et al.Cancers|March 28, 2024
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III DiseaseMaja Guberina, Christoph Pöttgen, Nika Guberina, et al.BMC Cancer|February 1, 2019
Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitroSabrina Borchert, Michael Wessolly, Jan Schmeller, et al.Signal Transduction and Targeted Therapy|February 25, 2026
Targeting fused in sarcoma (FUS): a novel antisense strategy for treating idiopathic pulmonary fibrosisBhavika B Katariya, Shashipavan Chillappagari, Lisa Arnold, et al.Pageof 27